CORC

浏览/检索结果: 共2条,第1-2条 帮助

限定条件                    
已选(0)清除 条数/页:   排序方式:
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA Oncology, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575
作者:  Han, Baohui*;  Li, Kai*;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载:7/0  |  提交时间:2019/12/03
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文
British Journal of Cancer, 2018, 卷号: 118, 期号: 5, 页码: 654-661
作者:  Han, Baohui*;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying
收藏  |  浏览/下载:9/0  |  提交时间:2019/12/03


©版权所有 ©2017 CSpace - Powered by CSpace